Across TCGA pan-cancer cohorts, PRSS1 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of PRSS1’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where PRSS1 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types PRSS1 is over-expressed in tumor, although a few such as PDAC and CCRCC show the opposite, repressed pattern.

PDAC, CCRCC, and LSCC are the cancer types where PRSS1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PRSS1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	Female	II,III,IV	−3.149	<.001	8	view →
CCRCC	Male	II,III,IV	−1.400	<.001	8	view →
LSCC	Male	All	−0.875	<.001	4	view →
LUAD	All	III,IV	−0.743	.023	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: PRSS1 RNA expression & survival · all PRSS1 data types